Skip to main content
. 2021 Feb 26;13(3):307. doi: 10.3390/pharmaceutics13030307

Figure 5.

Figure 5

IC50 of SIT (A), MEL (B), and combination of SIT-MEL (C) against SARS-CoV-2.